---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-006875"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2025-02-14T23:59:59+00:00"
generated_at: "2026-05-26T21:32:52.805348+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anebulo reports Q2 FY2025 net loss $2.5M ($0.09/sh); secures $15M private placement; FDA supports pediatric plan

## Summary
- Net loss for Q2 FY2025 (Dec 31, 2024) was $2.5M, or $0.09 per share, compared to $2.7M ($0.11) in prior year.
- Cash and equivalents $15.0M as of Dec 31, 2024; additional $3M available under amended loan.
- FDA acknowledged unmet need for pediatric cannabis toxicity treatment; Phase 1 SAD study of IV selonabant expected in H1 2025.
- Closed $15M private placement with 22NW Fund, issuing 15.2M shares.
- Amended loan with 22NW and JFL, reducing max to $3M and removing securitization.

## SEC filing metadata
- accession: 0001493152-25-006875
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2025-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315225006875/0001493152-25-006875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315225006875/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-006875
- JSON: https://secwatch.observer/filing/0001493152-25-006875.json
- Plain text: https://secwatch.observer/filing/0001493152-25-006875.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.